Table 4 |
||||||
|
Evolution of urinary melatonin, 6 sulfatoxymelatonin, and melatonin/6 sulfatoxymelatonin ratio |
||||||
|
Active group |
Placebo group |
|||||
|
|
|
|||||
|
Baseline |
End of Study |
Difference |
Baseline |
End of Study |
Difference |
|
|
|
||||||
|
Melatonin (ng/h), |
8.1 (5.9) |
10.3 (11.5) |
+2.2 (11.3) |
8.0 (5.4) |
7.3 (5.2) |
-0.7 (5.0) |
|
aMT6S (ng/h) |
362.9 (256.0) |
333.4 (206.2) |
-29.4 (138.2) |
291.0 (144.4) |
294.3 (144.5) |
+3.3 (111.2) |
|
Mel/aMT6S* |
0,0301 (0,0329) |
0,0339 (0,0327) |
+0,004 (0,037) |
0,0301 (0,0201) |
0,0319 (0,0327) |
+0,002 (0,030) |
|
|
||||||
|
Mean (standard deviation) * mean of all patients ratios |
||||||
|
Cornu et al. BMC Complementary and Alternative Medicine 2010 10:29 doi:10.1186/1472-6882-10-29 |
||||||
